PNEUMOCOCCAL VACCINE - PNEUMOCOCCAL VACCINATION - PNEUMOCOCCAL VACCINES - PNEUMOCOCCAL IMMUNIZATION - ADULT IMMUNIZATIONS

 
FOR HEALTH CARE PROVIDERS
Pneumococcal Disease
Why you should vaccinate adults against pneumococcal disease
  • Invasive pneumococcal infection kills thousands of people in the U.S. each year. In 2006, about 41,000 cases of invasive disease caused 5,000 U.S. deaths, most of which occurred among those aged 65 and older.

  • Approximately half of the deaths occurring annually from pneumococcal infection could be prevented through use of the vaccine.

  • As many as 175,000 people are hospitalized due to pneumococcal pneumonia in the U.S. each year. The case-fatality rate of pneumococcal pneumonia is 5 to 7 percent and may be much higher among the elderly.

  • More than 50,000 cases of pneumococcal bacteremia occur in the U.S. each year. The overall case-fatality rate for bacteremia is about 20 percent, but may be as high as 60 percent among the elderly.

  • Approximately 3,000 to 6,000 cases of pneumococcal meningitis occur each year in the U.S. The case-fatality rate of pneumococcal meningitis is approximately 30 percent, but may be as high as 80 percent among the elderly.
 
NFID’s Pneumococcal Disease Advisory Board’s Statement

Higher Pneumococcal Disease Vaccination Rates Needed to Protect More At-Risk US Adults

Published in Postgraduate Medicine

 
 
Read More
For more information about pneumococcal disease, click here.
 
 
CME Activities on Medscape
Pneumococcal Disease in an Older Patient With Chronic Lung Disease: A Teaching Case

Pneumococcal Disease in Adults: Identifying Risk and Preventive Approaches in the Face of Changing Epidemiology
 
Contact Us  |  About NFID  |  Adult Immunization Report  |  Supporting Organizations This Web site is supported by unrestricted educational grants to the National Foundation for Infectious Diseases from GlaxoSmithKline, Merck & Co., Inc., sanofi pasteur and Wyeth Pharmaceuticals.